As effective OV treatment has been reported to remodel the TME to favor PD-1 and/or PD-L1 ICB therapy43, we hypothesized that OV-BYTE therapy would show a synergistic anti-tumor response with PD-1 and/or PD-L1 ICB therapy. This evidence concerns the gene PDCD1 and neoplasm.